NortheastPop. 19.5M

GLP-1 Coverage & Costs in New York (2026)

$79/month (Embody, compounded semaglutide, monthly plan) is the lowest monthly-plan price we have recorded among the programs on this page. Embody lists 48 states and our records do not name them, so confirm New York at intake.

The lowest recorded compounded tirzepatide price is $129/month (Embody, monthly plan). Among programs recorded as available in all 50 states, the lowest is $139/month (AgelessRx, compounded semaglutide, monthly plan). 6 of the 49 programs listed have no recorded price. Recorded prices cover medication and known program fees, not a verified total.

Medicaid: not covered as of January 2026 (KFF)
Eduard Cristea
Eduard Cristea
Published: |Updated:

New York Medicaid Coverage for GLP-1

Medicaid: not covered as of January 2026 (KFF)

KFF's map lists New York as not covering GLP-1s for obesity under fee-for-service as of January 2026. Rules and later changes are not on that map, so confirm with the state Medicaid agency or your plan.

Your Options in New York:

  • Telehealth programs: recorded compounded prices from $79/month on a monthly plan, where the program serves New York
  • Commercial or employer insurance: check your plan's drug list and prior authorization rules
  • Medicare GLP-1 Bridge for eligible Part D enrollees (see below)

New York Medicaid GLP-1 Prescriptions in 2025

Prescriptions paid

815,882

Rank of 51

#3

Medicaid paid, before rebates

$929.5 million

Most-filled product

Ozempic

New York Medicaid paid for 815,882 GLP-1 prescriptions in 2025, 7.2% of the 11.26 million paid nationally and number 3 of 51 (50 states and DC). It reimbursed pharmacies $929.5 million before manufacturer rebates, about $1,139 per prescription, and the most-filled product was Ozempic. These counts include diabetes prescriptions, not only weight loss. Wegovy, Zepbound and Saxenda, the brands approved for chronic weight management, made up 208 of those prescriptions (0%). Wegovy and Zepbound also carry other approved uses, so this is an upper bound on weight-loss use, not a count of it.

From 2021 to 2025, New York Medicaid GLP-1 prescriptions went from 356,525 to 815,882, 2.3 times the 2021 count. From 2024 to 2025 the count rose by 111,547.

2021

356,525

2022

487,606

2023

649,555

2024

704,335

2025

815,882

ProductNY Medicaid prescriptions, 2025Share
Ozempic464,37156.9%
Mounjaro218,86426.8%
Trulicity103,67212.7%
Rybelsus24,2523%
Liraglutide (generic)3,3910.4%
Victoza8160.1%
Bydureon308under 0.1%
Wegovy197under 0.1%
Zepbound11under 0.1%

Source: CMS State Drug Utilization Data, 2025 (updated July 13, 2026), fee-for-service and managed care, all four quarters, compiled in our network's PriceTracker GLP-1 state table (read October 4, 2026); 2021 to 2024 summed by us from CMS's own yearly datasets with the same method, read November 9, 2026. CMS hides rows under 11 prescriptions, so small counts are slightly low. CMS publishes no per-enrollee rate here, so a total reflects the size of the program as much as use.

New York Employee Plan and Insurer GLP-1 Rules

Empire Plan (NYSHIP)

Covers with limits

The Empire Plan's January 2026 Advanced Flexible Formulary lists Wegovy and Zepbound as preferred anti-obesity agents, each requiring prior authorization.

  • The 2026 preferred drug list, administered by CVS Caremark, groups Wegovy and Zepbound under anti-obesity agents and marks each PA (prior authorization).

    “ANTI-OBESITY AGENTS liraglutide PA CONTRAVE PA WEGOVY PA ZEPBOUND PA”

    Source: NYS Department of Civil Service. Read October 29, 2026.

  • The list describes itself as covered drugs by therapeutic class.

    “This list includes commonly prescribed covered drugs by therapeutic class, a list of commonly prescribed covered drugs in alphabetic order (Quick Reference Drug List), a list of commonly prescribed non-preferred (Level 3) drugs along with covered preferred drug alternatives, and a list of excluded drugs along with covered preferred drug alternatives.”

    Source: NYS Department of Civil Service. Read October 29, 2026.

We have no New Yorkinsurer policy on record yet. Most commercial plans decide GLP-1 coverage plan by plan, so the employer's choice matters as much as the insurer.

Comparing self-pay programs in New York?

2-minute quiz: filter by budget and medication preference.

Take the quiz →

Telehealth Programs to Check for New York

We list 49 programs here. 21 are recorded as available in all 50 states. 7 more publish their own state list, summarized below for New York. The rest record a state count without naming the states, so confirm New York with the program at intake before you pay.

What Programs' Own Pages Say About New York

8 of the 8 programs whose own pages name the states they serve include New York: Willow, SnagRx, Strut Health, MangoRx, Wellorithm, MEDGm, TelosRx, Trimi. Pages read November 9, 2026. This is what each seller states about availability, not a licensing check.

Trimi's state table lists New York as served through the Arora Health network. Visit format there: Online evaluation through the Arora Health network. The telehealth law it cites for New York is N.Y. Pub. Health Law 2999-cc. That citation is Trimi's, not our legal reading. Trimi state table, read November 9, 2026.

Programs on Our List, in Published Order

Compounded GLP-1 care with one-month and prepaid plans

Personalized GLP-1 consultations with tailored prescriptions and ongoing physician support

Affordable compounded semaglutide from $119/mo with free shipping and health coaching

From $119/mo semaglutide, from $185/mo tirzepatide, 12-month planCompounded Semaglutide, Compounded TirzepatideAll 50 States

Personalized GLP-1 weight loss with licensed providers and nationwide coverage

45 more programs on our list: 19 recorded as available in all 50 states, 7 with a state list shown in the table above, and 19 with a state count but no published list we have read. Compare all of them side by side.

Estimated GLP-1 Costs in New York

Best Value

Telehealth (Compounded)

$79 to $399/mo

Recorded monthly-plan prices for compounded semaglutide and tirzepatide. Availability varies by program, so confirm your state at intake.

Wegovy

Brand prices with and without insurance.

Zepbound

List, LillyDirect and savings card prices.

No insurance

Self-pay GLP-1 options without coverage.

The compounded range is our recorded monthly-plan prices, the same in every state. Brand and insurance costs depend on the plan, so we link the pages that carry their sources. Compounded medications are not FDA-approved.

Medicare Part D GLP-1 Claims in New York, 2024

New York prescribers wrote 1,473,609 Medicare Part D GLP-1 claims in 2024, number 3 of 51, with $1.91 billion in gross drug cost before rebates. Ozempic led with 705,203 claims for 132,492 enrollees. Wegovy had 17,464 claims. Part D did not pay for weight loss alone in 2024, so these fills are for diabetes and other approved uses.

ProductNY Part D claimsEnrollees
Ozempic705,203132,492
Trulicity307,21255,937
Mounjaro303,18454,615
Rybelsus114,73226,177
Wegovy17,4644,179
Victoza13,361Not given
Bydureon Bcise8,4951,812
Liraglutide3,3151,325
Byetta623151
Zepbound2018

Source: CMS Medicare Part D Prescribers by Geography and Drug, 2024 (updated May 21, 2026), state rows, read November 9, 2026. The state is the prescriber's. Claims include refills, and enrollees are not added across products because one person can fill two.

Now Live — Launched July 1, 2026

Medicare GLP-1 Bridge Program in New York

The Bridge is national, so the rules are the same in New York as everywhere: eligible Part D enrollees pay $50/month for Foundayo, Wegovy or Zepbound KwikPen, subject to BMI rules and exclusions. Medicare fact sheet.

Patient Cost

$50/mo

Launch Date

July 1, 2026

Runs Through

Dec 31, 2027

Read the Full Medicare Guide

How New York Compares to Other Northeast States

Medicaid coverage of GLP-1s for obesity is optional for states, so the answer differs by state. Here is how New York and its neighbors in the Northeast are recorded:

StateMedicaid and GLP-1s for obesityMedicaid GLP-1 Rx, 2025
New York (this page)Not covered815,882
ConnecticutNot covered174,430
MassachusettsNot covered399,014
New JerseyNot covered165,515
PennsylvaniaNot covered843,743

Our recorded telehealth prices are not state-specific: $79 to $399/month on monthly plans. Medicaid and marketplace coverage is what varies.

KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026. Managed care plans may differ. Later counts may be lower: The RX Index, an independent tracker, listed 11 in a July 10, 2026 snapshot and says that is not a current national count. Sources read November 6, 2026. Policies change, so confirm with your state Medicaid agency or plan.

GLP-1 Guides for New York Cities

If Your Insurance Denies GLP-1 Coverage in New York

Commercial plans offer an internal appeal, then external review; New York Medicaid enrollees can ask for a fair hearing. The denial letter names the deadlines.

How to Check Your Specific Plan in New York

  • New York Medicaid: Medicaid: not covered as of January 2026 (KFF). Ask your Medicaid plan for its drug list and prior authorization rules, or find the state agency on Medicaid.gov's state contacts.
  • State employees: Empire Plan (NYSHIP), covers with limits per the documents cited above. Confirm with the plan before you fill a prescription.
  • Any other plan: call the number on your card and ask whether Wegovy or Zepbound is covered for weight loss, which tier it sits on, and what prior authorization needs. Get the answer in writing.

Find the Right GLP-1 Provider in New York

Answer a few questions and we'll match you with the best GLP-1 program for your budget, insurance, and goals in New York.

Frequently Asked Questions — New York

Does New York Medicaid cover GLP-1 medications for weight loss?
KFF's map lists New York as not covering GLP-1s for obesity under fee-for-service as of January 2026. Rules and later changes are not on that map, so confirm with the state Medicaid agency or your plan. You can also look at telehealth programs (recorded monthly-plan prices from $79/month; confirm New York at intake), commercial insurance, or the Medicare GLP-1 Bridge.
How many GLP-1 prescriptions did New York Medicaid pay for in 2025?
New York Medicaid paid for 815,882 GLP-1 prescriptions in 2025, 7.2% of the 11.26 million paid nationally and number 3 of 51 (50 states and DC). It reimbursed pharmacies $929.5 million before manufacturer rebates, about $1,139 per prescription, and the most-filled product was Ozempic. These counts include diabetes prescriptions, not only weight loss. Wegovy, Zepbound and Saxenda, the brands approved for chronic weight management, made up 208 of those prescriptions (0%). Wegovy and Zepbound also carry other approved uses, so this is an upper bound on weight-loss use, not a count of it. From 2021 to 2025, New York Medicaid GLP-1 prescriptions went from 356,525 to 815,882, 2.3 times the 2021 count. From 2024 to 2025 the count rose by 111,547. Source: CMS State Drug Utilization Data, 2025 (updated July 13, 2026).
How many Medicare Part D GLP-1 claims were there in New York in 2024?
New York prescribers wrote 1,473,609 Medicare Part D GLP-1 claims in 2024, number 3 of 51, with $1.91 billion in gross drug cost before rebates. Ozempic led with 705,203 claims for 132,492 enrollees. Wegovy had 17,464 claims. Part D did not pay for weight loss alone in 2024, so these fills are for diabetes and other approved uses. Source: CMS Medicare Part D Prescribers by Geography and Drug, 2024 (updated May 21, 2026).
Does the New York state employee health plan cover GLP-1s for weight loss?
Empire Plan (NYSHIP): covers with limits. The Empire Plan's January 2026 Advanced Flexible Formulary lists Wegovy and Zepbound as preferred anti-obesity agents, each requiring prior authorization. Source: NYS Department of Civil Service, read October 29, 2026.
What is the cheapest way to get GLP-1 medication in New York?
The lowest monthly-plan price we have recorded among programs on this page is $79/month (Embody, compounded semaglutide, monthly plan). Embody lists 48 states and our records do not name them, so confirm New York at intake. Medicare Part D enrollees who qualify can get Foundayo, Wegovy or Zepbound KwikPen for $50/month through the Bridge.
Which online GLP-1 programs serve New York?
8 of the 8 programs whose own pages name the states they serve include New York: Willow, SnagRx, Strut Health, MangoRx, Wellorithm, MEDGm, TelosRx, Trimi. Pages read November 9, 2026. For the other programs on this page, confirm New York at intake before you pay.
Does Medicare cover GLP-1s in New York?
Yes for eligible Part D enrollees in New York: $50/month through the Medicare GLP-1 Bridge, July 1, 2026 to December 31, 2027, under the BMI rules in the Medicare section above.

Ready to start?

Compare the recorded costs, sources and evidence gaps for 52 listed providers. Confirm current terms with the provider before enrolling.

Embody (paid link)

from $49/mo, 12-month plan

Visit Embody